Champions Oncology Inc (CSBR):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Champions Oncology Inc (CSBR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C11528
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:45
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Champions Oncology Inc (Champions), formerly Champions Biotechnology Inc, is a developer of advanced technology solutions and services to personalize the development and use of oncology drugs. The company’s technology platform is an approach based upon the implantation of primary human tumors in immune-deficient mice followed by propagation of the resulting engraftments. It offers personalized tumorgraft development, drug studies and genome sequencing as part of personalized oncology solutions. The company also provides translational oncology solutions to oncologists, pharmaceutical and biotechnology companies. It has operations in the US and the UK. Champions is headquartered in Hackensack, New Jersey, the US.

Champions Oncology Inc (CSBR) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Champions Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Champions Oncology Enters into Agreement with NSABP Foundation and Puma Biotechnology 11
Champions Oncology Enters into Agreement with AstraZeneca 12
Champions Oncology Enters into Agreement with Addario 13
Addario Lung Cancer Medical Institute, Champions Oncology and ROS1ders Enter into Agreement 14
Champions Oncology Enters into Co-Development Agreement 15
Insilico Medicine Enters into Research Agreement with Champions Oncology 16
Champions Enters Into Drug Discovery And Development Agreement With Teva 17
Licensing Agreements 18
Champions Oncology Enters into Licensing Agreement with Pfizer 18
Equity Offering 19
Champions Oncology Raises USD5 Million in Public Offering of Shares 19
Champions Oncology Raises USD14 Million in Private Placement of Units 21
Champions Oncology Completes Private Placement Of Shares For US$9 Million 23
Champions Oncology Inc – Key Competitors 24
Champions Oncology Inc – Key Employees 25
Champions Oncology Inc – Locations And Subsidiaries 26
Head Office 26
Other Locations & Subsidiaries 26
Recent Developments 27
Strategy And Business Planning 27
Mar 16, 2017: Champions Oncology Announces Plan to Open New Lab Facility in Rockville, Maryland 27
Financial Announcements 28
Sep 13, 2018: Champions Oncology reports record quarterly revenue of $6.2 million 28
Jul 26, 2018: Champions Oncology Reports Record Annual Revenue Exceeding $20M for Fiscal Year Ended April 30, 2018 29
Mar 15, 2018: Champions Oncology Reports Quarterly Revenue of $5.1 Million 31
Dec 07, 2017: Champions Oncology Reports Record Quarterly Revenue of $5.2M 33
Sep 14, 2017: Champions Oncology Reports Record Quarterly Revenue of $5 Million 35
Jul 27, 2017: Champions Oncology Reports 38% Revenue Growth for Fiscal Year Ended April 30, 2017 37
Mar 16, 2017: Champions Oncology Reports 40% Revenue Growth 39
Government and Public Interest 41
Sep 26, 2017: Champions Oncology announces $2 million award from the National Cancer Institute to develop and evaluate prostate cancer PDX models 41
Product News 42
Sep 18, 2017: Champions Oncology announces publication highlighting clinical correlation between patient-derived xenograft model responses and patient responses to oncology therapies 42
Feb 16, 2017: Champions Oncology Announces New Collection of Patient-Derived Xenograft Models Available for Translational Research 43
Other Significant Developments 44
Feb 21, 2018: Motivated Patients with ROS1 Cancer Initiate Global Research Study 44
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
Champions Oncology Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Champions Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Champions Oncology Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Champions Oncology Enters into Agreement with NSABP Foundation and Puma Biotechnology 11
Champions Oncology Enters into Agreement with AstraZeneca 12
Champions Oncology Enters into Agreement with Addario 13
Addario Lung Cancer Medical Institute, Champions Oncology and ROS1ders Enter into Agreement 14
Champions Oncology Enters into Co-Development Agreement 15
Insilico Medicine Enters into Research Agreement with Champions Oncology 16
Champions Enters Into Drug Discovery And Development Agreement With Teva 17
Champions Oncology Enters into Licensing Agreement with Pfizer 18
Champions Oncology Raises USD5 Million in Public Offering of Shares 19
Champions Oncology Raises USD14 Million in Private Placement of Units 21
Champions Oncology Completes Private Placement Of Shares For US$9 Million 23
Champions Oncology Inc, Key Competitors 24
Champions Oncology Inc, Key Employees 25
Champions Oncology Inc, Other Locations 26
Champions Oncology Inc, Subsidiaries 26

List of Figures
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Champions Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Champions Oncology Inc (CSBR):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Casino Guichard-Perrachon SA:戦略・SWOT・企業財務分析
    Casino Guichard-Perrachon SA - Strategy, SWOT and Corporate Finance Report Summary Casino Guichard-Perrachon SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Checkpoint Surgical LLC-医療機器分野:企業M&A・提携分析
    Summary Checkpoint Surgical LLC (Checkpoint Surgical) is a medical device company that offers neuro-protective surgery equipment. The company offers neuro-protective devices including checkpoint stimulators and locators; and checkpoint head and neck systems. Its checkpoint stimulators and locators p …
  • Eu Yan Sang International Ltd:企業の戦略的SWOT分析
    Eu Yan Sang International Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Philex Mining Corp:企業の戦略・SWOT・財務情報
    Philex Mining Corp - Strategy, SWOT and Corporate Finance Report Summary Philex Mining Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Entek Energy Ltd (ETE):企業の財務・戦略的SWOT分析
    Entek Energy Ltd (ETE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • China Pioneer Pharma Holdings Ltd (1345):企業の財務・戦略的SWOT分析
    Summary China Pioneer Pharma Holdings Ltd (Pioneer Pharma) is an investment holding company that markets and promotes pharmaceutical products and medical devices. The company offers pharmaceutical products such as anti-inflammatory medicines, pain management, orthopedics, opthalmology, chronic obstr …
  • ThermoGenesis Holdings Inc (THMO):企業の財務・戦略的SWOT分析
    ThermoGenesis Holdings Inc (THMO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Semma Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Semma Therapeutics Inc (Semma Therapeutics) is a biotechnology company that develops cell replacement therapy for the treatment of diabetes. The company develops therapies using stem cells of the individuals with Type 1 diabetes to produce their own insulin that will regulate the blood sugar …
  • Renova Energia SA (RNEW11)-エネルギー分野:企業M&A・提携分析
    Summary Renova Energia S.A. (Renova Energia) is a renewable power generation company. It develops, implements and operates power generation projects based on renewable energy sources such as wind, small hydropower and solar; and sells electricity. It also undertakes activities related to manufacturi …
  • PZ Cussons Nigeria Plc:企業の戦略・SWOT・財務情報
    PZ Cussons Nigeria Plc - Strategy, SWOT and Corporate Finance Report Summary PZ Cussons Nigeria Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Enanta Pharmaceuticals Inc (ENTA):企業の財務・戦略的SWOT分析
    Summary Enanta Pharmaceuticals Inc (Enanta) is a biotechnology company that discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company’s lead product candidate includes EDP-305, a farnesoid X receptor (FXR) agonist intended for the treatment of …
  • DXI Energy Inc (DXI):石油・ガス:M&Aディール及び事業提携情報
    Summary DXI Energy Inc (DXI Energy), formerly Dejour Energy Inc is an upstream oil and gas company. The company undertakes the business of oil and gas exploration, distribution and production. It explores for oil and gas properties in regions of Colorado and British Columbia. DXI Energy operates pro …
  • Biocept Inc (BIOC)-製薬・医療分野:企業M&A・提携分析
    Summary Biocept Inc (Biocept) is a developer of diagnostic solutions. The company provides biopharmaceutical and clinical research, and molecular oncology laboratory services. It provides tests for various solid tumor cancers. Biocept offers related instrumentation, OncoCEE technology, and analytica …
  • CIC Insurance Group Limited (CIC):企業の財務・戦略的SWOT分析
    CIC Insurance Group Limited (CIC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • ObsEva SA (OBSV):企業の財務・戦略的SWOT分析
    ObsEva SA (OBSV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Statnett SF:企業の戦略的SWOT分析
    Statnett SF - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • WSI Industries, Inc.:企業の戦略・SWOT・財務情報
    WSI Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary WSI Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • National Reinsurance Corporation Of The Philippines:企業の戦略・SWOT・財務分析
    National Reinsurance Corporation Of The Philippines - Strategy, SWOT and Corporate Finance Report Summary National Reinsurance Corporation Of The Philippines - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's stru …
  • Neuraltus Pharmaceuticals Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Neuraltus Pharmaceuticals Inc (Neuraltus) is a biopharmaceutical company that develops and commercializes therapeutics for neurodegenerative diseases. The company offers products under clinical development that include NP001 and others. It develops macrophage which is based on the recent und …
  • CapitaLand Ltd:戦略・SWOT・企業財務分析
    CapitaLand Ltd - Strategy, SWOT and Corporate Finance Report Summary CapitaLand Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆